Inventor
Mohammed T. QATANANI
Inventor
US
Overview
Patents· 52 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
C07KPeptides25%
C12NMicroorganisms or enzymes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12YEnzymes10%
PatentTitleYear
12,496,352Muscle targeting complexes and uses thereof for treating myotonic dystrophy202512,478,687United states202512,460,011Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject202512,440,575Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,440,574Muscle targeting complexes and formulations for treating myotonic dystrophy202512,428,487Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject202512,403,203Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,397,062Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,370,264Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject202512,357,703Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping202512,329,825Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject202512,329,824Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,325,753Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy202512,319,743Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject202512,280,122Muscle targeting complexes and uses thereof for treating myotonic dystrophy202512,263,225Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy202512,239,716Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,239,717Muscle targeting complexes and uses thereof for treating dystrophinopathies202512,173,078Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide202412,173,079Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide202412,144,867Muscle targeting complexes and uses thereof for treating dystrophinopathies202412,144,868Muscle targeting complexes and uses thereof for treating dystrophinopathies202412,128,109Muscle targeting complexes and formulations for treating dystrophinopathies202412,102,687Muscle targeting complexes and uses thereof for treating myotonic dystrophy202412,097,263Muscle targeting complexes and uses thereof for treating myotonic dystrophy202412,018,087Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject202412,012,460Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide202412,005,124Muscle targeting complexes and uses thereof for treating dystrophinopathies202411,986,537Muscle targeting complexes and uses thereof for treating dystrophinopathies202411,969,475Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy202411,931,421Muscle targeting complexes and formulations for treating myotonic dystrophy202411,911,484Muscle targeting complexes and uses thereof for treating myotonic dystrophy202411,844,843Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy202311,839,660Anti-transferrin receptor antibody and uses thereof202311,833,217Muscle targeting complexes and uses thereof for treating dystrophinopathies202311,795,233Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide202311,795,234Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide202311,787,869Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness202311,771,776Muscle targeting complexes and uses thereof for treating dystrophinopathies202311,759,525Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy202311,679,161Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy202311,672,872Anti-transferrin receptor antibody and uses thereof202311,648,318Anti-transferrin receptor (TFR) antibody and uses thereof202311,638,761Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy202311,633,496Muscle targeting complexes and uses thereof for treating dystrophinopathies202311,633,498Muscle targeting complexes and uses thereof for treating myotonic dystrophy202311,518,816Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy202211,497,815Muscle targeting complexes and uses thereof for treating dystrophinopathies202211,390,682Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy202211,369,689Muscle targeting complexes and uses thereof for treating dystrophinopathies202211,286,305Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA202211,248,056Muscle targeting complexes and uses thereof for treating dystrophinopathies2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to DYNE THERAPEUTICS INC (52)· patent assignee history
2022–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| DYNE THERAPEUTICS INC | 52 | 2022–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 52 | 2022–2025 |